- Home
- LRE vs BIVI Comparison
LRE vs BIVI Comparison
Compare LRE & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- BIVI
- Stock Information
- Founded
- LRE 2001
- BIVI 2013
- Country
- LRE Japan
- BIVI United States
- Employees
- LRE N/A
- BIVI N/A
- Industry
- LRE
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- BIVI Health Care
- Exchange
- LRE Nasdaq
- BIVI Nasdaq
- Market Cap
- LRE 19.2M
- BIVI 20.4M
- IPO Year
- LRE 2023
- BIVI N/A
- Fundamental
- Price
- LRE $1.51
- BIVI $1.19
- Analyst Decision
- LRE
- BIVI Strong Buy
- Analyst Count
- LRE 0
- BIVI 2
- Target Price
- LRE N/A
- BIVI $40.00
- AVG Volume (30 Days)
- LRE 7.4K
- BIVI 284.3K
- Earning Date
- LRE 01-01-0001
- BIVI 11-06-2024
- Dividend Yield
- LRE N/A
- BIVI N/A
- EPS Growth
- LRE N/A
- BIVI N/A
- EPS
- LRE 0.25
- BIVI N/A
- Revenue
- LRE $118,414,146.00
- BIVI N/A
- Revenue This Year
- LRE N/A
- BIVI N/A
- Revenue Next Year
- LRE N/A
- BIVI N/A
- P/E Ratio
- LRE $6.00
- BIVI N/A
- Revenue Growth
- LRE 14.65
- BIVI N/A
- 52 Week Low
- LRE $1.19
- BIVI $1.04
- 52 Week High
- LRE $13.76
- BIVI $58.20
- Technical
- Relative Strength Index (RSI)
- LRE 48.23
- BIVI 26.50
- Support Level
- LRE $1.51
- BIVI $1.09
- Resistance Level
- LRE $1.63
- BIVI $1.24
- Average True Range (ATR)
- LRE 0.10
- BIVI 0.15
- MACD
- LRE 0.03
- BIVI -0.09
- Stochastic Oscillator
- LRE 65.79
- BIVI 7.25
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo and Kanagawa prefecture. It operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. It generates revenue from developing and selling single-family homes and condominiums. The company's primary and sole operating segment is real estate sales.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.